Business Trends– category –
-
Quad-targeting CAR T cells: Phase 1 trial results for DIPG/DMG
Research Square (preprint) Overview A first-in-human phase 1 trial (BrainChild-04) demonstrated that repetitive intracerebroventricular administration of quad-targeting CAR T cells is feasible and tolerable in children and young adults w... -
Enzell: Commercial CCPC Designation for Global CAR-T Therapy
Newspim South Korea Overview Enzell has been designated as a commercial Centralized Cell Processing Center (CCPC) by a global pharmaceutical company for CAR-T therapy production. The company has also developed a proprietary process that ... -
Samsung Biologics: Custom CMC Platform for Bispecific Antibodies
Seoul Economic Daily South Korea Overview Samsung Biologics has introduced a customized chemistry, manufacturing, and controls (CMC) platform designed to optimize the development of complex bispecific antibodies. The platform reduces the... -
CAR-T Therapy: Hong Kong Team’s 14-Day Manufacturing Timeline
BIOENGINEER.ORG China（Hong Kong） Overview Researchers in Hong Kong developed a fully automated, locally based manufacturing system that produces CD19-targeted CAR-T cell therapy in 14 days. All six pediatric patients with relapsed B-ce... -
Off-the-Shelf CAR T: Factors Shaping Allogeneic Therapy Success
BIOENGINEER.ORG USA Overview Researchers at The University of Texas MD Anderson Cancer Center identified immune rejection and intrinsic cell fitness as the two decisive factors determining the success of off-the-shelf CAR T cell therapie... -
Alcon: $550 Million Acquisition of Neurotech and Encelto Therapy
BioPharm International USA Overview Alcon has acquired Neurotech Pharmaceuticals for $550 million to integrate Encelto, the only FDA-approved treatment for idiopathic macular telangiectasia type 2 (MacTel). The deal adds an encapsulated ... -
Syntax Bio Cellgorithm: iPSC to Beta Cell Programming in 4 Days
Business Wire (Yahoo Finance) USA Overview Syntax Bio has demonstrated the ability to differentiate human induced pluripotent stem cells (iPSC) into pancreatic beta cells within four days using its Cellgorithm platform. By utilizing CRIS... -
Wharton’s Jelly EV Platform: GMP-Compliant Production Specs
BIOENGINEER.ORG Spain Overview Spanish researchers have developed a semi-automated, GMP-compliant platform to produce clinical-grade extracellular vesicles (EVs) from Wharton’s jelly-derived mesenchymal stromal cells (MSCs). The system i... -
Alg-MR-MS: Dual-crosslinkable microspheres for cell expansion
Biomedical Materials Australia Overview Researchers have developed Alginate-methacrylate-RGD microspheres (Alg-MR-MS) that integrate scalable cell expansion and scaffold formation into a single platform. Human adipose-derived stem cells ... -
Graphene Oxide: Boosting Stem Cell Exosome Yield for Wound Healing
(Scientific publication or industry news, likely based on Materials Today Bio) South Korea Overview Researchers have developed a method using graphene oxide to transform induced pluripotent stem cell spheroids into high-output "exosome f...
